Skip to main content

Table 3 Summary of Adverse Events

From: A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya

Adverse event

AL tablets

n = 133* (%)

AL suspension

n = 134* (%)

p

Diarrhoea

11 (8.3)

10 (7.4)

0.81

Vomiting during treatment**

21 (2.6)

12 (3.0)

0.72

Rhinitis

17(12.8)

22 (16.4)

0.40

Otitis Media

1 (0.8)

5 (3.7)

0.21

Pneumonia

3 (2.3)

6 (4.5)

0.50

Bacterial skin infections

5 (3.8)

5 (3.7)

1.00

Fungal skin infections

6 (4.5)

5 (3.7)

0.98

Eczematous rash

1(0.8)

5 (3.7)

0.21

Contact dermatitis

1 (0.8)

1 (0.7)

1.00

Conjunctivitis

6 (4.5)

7 (5.2)

0.98

  1. * n = total number of children randomized to the treatments
  2. ** Vomiting episodes as a proportion of number of treatment doses administered